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ABSTRAK 
TARIGAN, S., R. INDRYANI, DARMINTO dan J. IGNJATOVIC. 2008. Purifikasi neuraminidase virus influenza subtipe H5N1. JITV 
14(1): 75-82. 
Neuraminidase pada virus influenza memainkan peranan yang vital dalam keberlangsungan kehidupan virus. Vaksinasi 
hewan dengan glikoprotein ini menghasilkan respon imun yang dapat melindungi hewan dari infeksi. Suplementasi vaksin 
konvensional dengan neuraminidase terbukti meningkatkan proteksi dan masa pakai vaksin. Neuraminidase yang dimurnikan 
dapat juga dipakai untuk pembuatan alat uji serologis untuk membedakan hewan yang positif avian influenza secara serologis 
akibat vaksinasi atau akibat infeksi. Dalam penelitian ini diuraikan cara purifikasi neuraminidase virus influenza suptipe H5N1. 
Triton X-100 dan Octyl β-D-glucopyranoside digunakan untuk mengekstraksi dan melarutkan glikoprotein membrane tersebut. 
Aktivitas enzimatik diukur menggunakan suatu uji yang sederhana, sensitif dan cocok dengan pekerjaan purifikasi tersebut; 
menggunakan substrat flourokrom 4-methylumbelliferyl-α-D-N-acetyl neuraminic acid. Nuraminidase diabsorbsi secara selektif 
dengan oxamic-acid agarose. Tingkat kemurnian neuraminidase yang dielusi dari kolom tersebut sebenarnya sudah cukup tinggi. 
Kemurnian yang lebih tinggi lagi diperoleh dengan separasi dengan gel filtrasi menggunakan Superdex-200. Neuraminidase 
yang dimurnikan tersebut aktif secara enzimatis dan tidak mengandung hemagglutinin yang terdeteksi baik dengan uji 
hemagglutinasi maupun dengan antibodi spesifik terhadap hemaglutinin H5N1. Neuraminidase yang dimurnikan tersebut 
dikenali  secara kuat oleh antibodi terhadap suatu daerah pada bagian tengah molekul neuraminidase tetapi hanya dikenali secara 
lemah oleh antibodi terhadap suatu daerah pada C-terminal neuraminidase virus H5N1. Neuraminidase yang dimurnikan tersebut 
terdapat dalam bentuk tetramer tetapi terurai menjadi bentuk monomer pada SDS PAGE reduksi, atau sebagian besar bentuk 
dimer pada SDS PAGE non reduksi. 
Kata kunci: Neuraminidase, Influenza, H5N1, Methylumbelliferyl, Oxamic-acid 
ABSTRACT 
TARIGAN, S., R. INDRYANI, DARMINTO and J. IGNJATOVIC. 2008. Purification of neuraminidase from Influenza virus subtype 
H5N1. JITV 14(1): 75-82. 
Influenza-virus neuraminidase plays vital role in the survival of the organisms. Vaccination of animals with this glycoprotein 
confers immune responses so that enable it to protect the animals from incoming infection. Supplementation of conventional 
vaccines with this glycoprotein increases the protection and longevity of the vaccine. Purified neuraminidase can also be used to 
develop serological tests for differentiation of serologically positive animals due to infection or to vaccination. In this study 
purification of neuraminidase from influenza virus subtype H5N1 was described. Triton x-100 and Octyl β-D-glucopyranoside 
were used to extract and diluted the glycoprotein membrane. The enzymatic activity of the neuraminidase was assayed using a 
fluorochrome substrate, 4-methylumbelliferyl-α-D-N-acetyl neuraminic acid, which was found to be simple, sensitive and 
suitable for the purification purpose. The neuraminidase was absorbed selectively on an oxamic-acid agarose column. The purity 
of neuraminidase eluted from this affinity column was high. A higher purity of the neuraminidase was obtained by further 
separation with gel filtration on Superdex-200. The purified neuraminidase was enzymatically active and did not contain any 
detectable haemagglutinin, either by haemagglutination assay or by monospecific antibodies raised against H5N1 hemagglutinin.  
The purified neuraminidase was recognized strongly by antibodies raised against an internal but only weakly by that against C-
terminal regions of the neuraminidase protein of H5N1-influenza virus. The purified neuraminidase was in tetrameric forms but 
dissociated into monomeric form on reducing condition, or mostly dimeric form on non-reducing SDS-PAGE. 
Key Words: Neuraminidase, Influenza, H5N1, Methylumbelliferyl, Oxamic-acid 
 
INTRODUCTION 
Avian influenza caused by influenza virus subtype 
H5N1 has been one of the most feared infection and has 
become the most publiciz           ed disease since 2003. 
The poultry industries have suffered enormous 
economic losses from massive number of chicken 
deaths and increased expenses for prophylaxis and 
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biosecurity. The virus causes not only substantial 
economic losses but also has the potential to cause a 
global pandemic of human influenza. Signalling the 
threat is the increasing number of people that have 
become infected by the virus; in Indonesia alone, from 
137 confirmed cases until 20 July 2008, 112 cases were 
fatal (WHO, 2008).  
Influenza viruses have two types of glycoproteins, 
haemagglutinin (HA) and neuraminidase (NA). The HA 
binds to a sialoglycan receptor on the target cell surface 
and mediates fusion of the viral envelope with the 
endosomal membrane in order to deliver viral genome 
into the cytoplasm of the target cells. The NA promotes 
the release of progeny virus from infected cells by 
destroying receptors on the host cell through hydrolysis 
of terminal sialic acids of sialoglycans (KLENK and 
ROTT, 1988; SKEHEL and WILLEY, 2000). Antibodies to 
the HA are protective and it neutralize viruses which 
are closely matched antigenically, whereas those to the 
NA are also protective but infection-permissive (DEROO 
et al., 1996; JOHANSSON et al., 1989). When animals 
are immunised with the same amount of purified HA 
and NA, the titre of conferred antibody against NA is 
comparable to that against HA, indicating both 
glycoproteins are equally immunogenic (JOHANSSON et 
al., 1989). However, immunisation of animals with 
conventional vaccines confers antibodies most of which 
are directed toward HA. The antibody levels towards 
NA is much lower, or undetected, especially following 
primary immunisation. This is because HA exist in 
much higher molar ratio in the virion (JOHANSSON and 
KILBOURNE, 1990). Since in conventional vaccine 
protection is attributed to the HA, changes in the HA 
due to antigenic drift may result in vaccination failure. 
Neuraminidase also undergoes antigenic drift but its 
rate is much slower. For that reason, inclusion of NA in 
a vaccine against influenza reduces the occurrence of 
vaccination failure (JOHANSSON and BRETT, 2007; 
JOHANSSON et al., 1998).  
One of the disadvantages of vaccination policy to 
control avian influenza is the difficulty in 
differentiating chicken serologically positive due to 
infection or vaccination, and this greatly impedes the 
surveillance and control programmes. One strategy that 
has been demonstrated to be effective for the 
differentiating infected from vaccinated animals 
(DIVA) is the ‘heterologous NA strategy’(CAPUA et al., 
2002). This strategy requires that chicken are 
vaccinated with vaccines containing the same HA 
subtype as the challenge virus but a different NA 
subtype. Infection is monitored by a serological test that 
is used to detect antibody to the NA subtype of the 
challenge or field virus. This strategy has been planned 
to be used in Indonesia. Heterologous H5N2 vaccines 
have been introduced and intended to replace the H5N1 
vaccines. If this strategy was implemented successfully, 
the prevalence of ongoing H5N1 infection could then be 
easily monitored by the presence of antibodies to N1-
neuraminidase. For this approach the availability of a 
serological test for detection of the antibodies to N1 
neuraminidase is essential. Development of such test 
however requires purified NA from the H5N1 virus, 
and this was attempted in this study.  
A number of methods for purification of influenza-
virus NA have been available. The influenza virus 
glycoproteins can be separated from the virion by 
various detergents and separated  either by anion 
exchange chromatography (JOHANSSON et al., 1989), 
oxamic-acid affinity chromatography (DEROO et al., 
1996) or immuno-affinity chromatography (GERENTES 
et al., 1996). As an alternative to the detergents, some 
worker demonstrated the use of proteases (pronase, 
bromelain or trypsin) to selectively cleavage the NA 
heads (AITKEN and HANNOUN, 1980; BURMEISTER et 
al., 1991; MCKIMM-BRESCHKIN et al., 1991). The NA 
is separated from the protease by a gel filtration 
chromatography.  
The NA of H5N1 virus, as far as we were aware, 
has not been purified to date. This subtype of influenza 
virus is much more virulence than those whose NA 
have been purified previously. This high virulence of 
H5N1 virus causes lower amount of virus to be 
produced during the passage of virus inoculated chicken 
embryos.  In addition, the amount and type of proteins 
in the harvested alantoic fluid may also be different 
compared to those with the less virulent viruses. For 
that reason some modification of the published methods 
may be necessary. The present study demonstrates the 
effectiveness of the approach taken in which Octyl β-D-
glucopyranoside and Triton X-100 were used for 
extraction and solubilisation, umbelliferyl assay for 
detection, and oxamic-acid-affinity and Superdex-200 
gel filtration chromatographies for separation of the 
H5N1-virus NA. 
MATERIALS AND METHODS 
Virus isolation 
The influenza virus subtype H5N1 used in this study 
was isolated from a hen dying during an avian influenza 
outbreak in Gunung Sindur Bogor, West Java, 
Indonesia in 2003 (A/Ck/West Java/1067/2003). This 
isolate is genetically similar to the Indonesian reference 
strain A/Ck/Bl/2003 (Dr. Indi NPL Dharmayanti, 
personal communication).  
Extraction and purification of neuraminidase 
The virus was grown by innoculating 11-day-
specific-pathogen-free-chicken embryos with 103 lethal 
egg dose (LED)/egg.  After 30 hour incubation at 37°C, 
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allantoic fluid was collected and clarified at 5 000 x g 
for 30 minutes. The virus particles contained in the fluid 
were pelleted at 35 000 x g for 30 minutes, suspended 
in PBS at about 1/300 original volume and kept at -
70oC until used. Extraction of NA from the viral 
particles was performed according to a previous method 
(HOCART et al., 1995). Briefly, an equal volume of 6% 
Triton X-100 (Sigma Aldrich chemicals) solution in 0.3 
M sodium acetate (pH 5.5) containing 2 mM 
phenylmethanesulfonyl fluoride (PMSF) (Sigma 
Aldrich Chemicals) was added to the freshly thawed 
viral suspension and stirred for 1 hour at 25oC. 
Insoluble viral materials were pelletted at 35 000 x g for 
30 minutes, the HA/ NA rich material contained in the 
supernatant was removed. The NA was purified from 
the HA/ NA rich supernatant by an affinity 
chromatography. A 5-ml N-(p-aminophenyl) oxamic 
acid agarose (Sigma Aldrich chemicals) was packed 
into a PD-10 column (Bio Rad Laboratories), activated 
by washing with 6 column volumes (CV) of 0.1 M 
sodium bicarbonate buffer (pH 9.1) containing 0.1% 
Octyl β-D-glucopyranoside (Sigma Aldrich chemicals) 
followed by 5 CV of 0.05 M sodium acetate buffer pH 
5.5 containing 0.1% Octyl β-D-glucopyranoside. The 
HA/NA-rich supernatant was loaded into the column; 
unbound materials were removed by washing the 
column with 10 CV of 0.15 M sodium acetate buffer 
containing 0.1% Octyl β-D-glucopyranoside. Bound 
NA was eluted from the column with 5 CV of 0.1 M 
sodium bicarbonate buffer containing 0.1% Octyl β-D-
glucopyranoside and 2 mM CaCl2. The NA-rich 
solution was concentrated to about 10% original 
volume using a 10-kDa-molecular-cut-off-spin 
concentrator.  
Further purification of the NA was performed on gel 
filtration chromatography using a 65 x 1.5 cm, 
superdex-200 column (Amersham Pharmacia Biotech). 
A 2-ml- volume of the concentrated oxamic-acid 
absorbed protein solution was loaded into the column, 
proteins were eluted from the column with a solution 
containing 40 mM sodium acetate, 150 mM NaCl, and 2 
mM CaCl2 pH 7.0 at a flow rate of 0.7 ml-1. Fractions 
(2.5 ml) were collected and NA content in each fraction 
was determined. Fractions containing NA were pooled 
and concentrated. 
Neuraminidase activity 
Neuraminidase activity was detected using a 
fluorochrome 4-methylumbelliferyl-α-D-N-acetyl 
neuraminic acid (Sigma Aldrich chemicals) as a 
substrate of the enzyme. The substrate was first diluted 
in double distil deionised H2O at 5 mM concentration, 
aliquoted then keep at -20oC until use. A 5 µl volume of 
freshly thawed substrate was added to an equal volume 
of serially diluted sample, mixed and incubated for 10  
minutes at 37oC. A 5-µl volume of this mixture was 
placed on the surface of a dark-coloured ceramic plate 
and examined under a 10-watt UV light. This UV light 
was similar to that shop keepers use to examine 
counterfeit money. The intensity of fluorescence 
emitted by the mixture corresponded to the NA activity 
of the sample. 
Enzyme linked immunosorbent assay (ELISA) 
In addition to the ‘methylumbelliferyl assay’, the 
presence of N1 NA is also confirmed with an ELISA 
using a panel of antibodies: (1) anti-Neuraminidase CT 
(specific antibodies raised against synthetic peptide 
with sequence similar to a 15 conserved amino acid at 
carboxy terminus of H5N1 NA protein (Genbank 
accession no. CAC95053), (2) anti-neuraminidase IN 
(specific antibodies raised against synthetic peptide 
with sequence similar to a 16 conserved amino in the 
middle of H5N1 NA protein (Genbank accession no. 
CAC95053), (3) anti-hemagglutinin NT (specific 
antibodies raised against synthetic peptide with 
sequence similar to a 15 conserved amino acid at amino 
terminus of H5N1 hemagglutinin protein (Genbank 
accession no. AAT76166), and (4) anti-hemagglutinin 
IN (specific antibodies raised against synthetic peptide 
with sequence similar to 14 conserved amino acid in the 
middle of H5N1 hemagglutinin protein (Genbank 
accession no. AAT76166). All of those antibodies were 
obtained from Proscience Inc. Poway CA (USA). 
ELISA was performed according to the procedure 
provided by the antibodies’ producer. 
SDS PAGE and Immunoblotting 
The SDS-PAGE was performed in a Mini-Protean-3 
cell (Bio Rad Laboratories). Stacking and separating 
gels contained 4% and 10% acrylamide, respectively. A 
20-µl volume of samples containing about 100 µg 
protein and 1x reduced or non reduced sample buffer 
were loaded into the gels and electrophoresis was run 
until the leading dye reached about 0.5 cm from the 
bottom of the gel. Detergent contained in the samples 
were removed before loading by methanol and 
chloroform precipitation (ROSENBERG, 1996). Separated 
proteins in one set of the gel were stained with 
Coomasie blue, whereas those in the other set were 
transferred onto a nitrocellulose membrane using a Mini 
Transblot (Bio Rad laboratories) and a transfer buffer 
consisting of 25 mM Tris, 192 mM glycine and 20% 
methanol. Proteins in the blot were incubated with 
serum from chicken previously immunised with an 
inactivated H5N1 vaccine then, probed with 
horseradish-peroxidise-labelled anti-chicken IgY 
(Sigma Aldrich chemicals). 
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RESULTS 
The N-(p-aminophenyl) oxamic acid agarose 
absorbed NA selectively from the Triton extract of the 
H5N1 virus. From 510 inoculated embryonated eggs, 
about 60 ml eluate from the oxamic-acid column was 
obtained. After adjusting the pH of the eluate to about 7 
and concentrating to 2.3 ml, the concentrated eluate 
contained 0.63 mg/ml of total protein. Its NA enzymatic 
activity was detected in 10-6 dilution by the 
‘methylumbelliferyl assay’. No hemagglutination 
activity was detected in this eluate either before or after 
the concentration. When this concentrated sample was 
fractionated further with a gel-filtration 
chromatography using a high resolution media, 
Superdex-200, it contained almost exclusively a single 
protein or at least a group of proteins of similar size 
(Figure 1). Based on our previous experience with 
similar Superdex-200 column, proteins eluted at that 
elution volume had a molecular weight of about 200 
kDa. This major elute contained NA but not 
hemagglutinating activity.  Only a small proportion of 
protein(s) (<10%), peaked at 105 ml elution volume, 
accompanied the major peak (Figure 1). This protein, or 
group of proteins, were predicted to have a molecular 
weight of about 50 kDa. Neuraminidase and 
hemagglutinating activities were not detected in this 
minor eluate.  
The umbelliferyl and hemagglutination assays 
which showed that the aminophenyl-oxamic-absorbed 
H5N1 proteins contained exclusively NA, without 
contaminating haemagglutinin agreed with ELISA 
results. In ELISA, the protein recognized strongly by 
anti neuraminidase-IN antibody, and weakly by anti 
neuraminidase-CT antibody (Figure 2). The oxamic-
acid absorbed protein did not recognized by specific 
antibodies to H5-hemagglutinin, neither by antibody to 
the N-terminal region nor by antibody to a middle 
region of H5N1 hemagglutinin (Figure 2). Similar 
results were obtained from ELISA experiment on the 
gel-filtration-purified oxamic-acid-absorbed protein 
(Figure 3).  
Results of SDS-PAGE and immunoblot analyses 
from different stage of NA purification are presented in 
Figure 4. The banding patterns of proteins in non-
reduced samples were different from those of reduced 
counterpart, indicating the presence of intensive 
disulphide bonding. Some of the major proteins that 
were present in the whole viral proteins were absent in 
the Triton X-100 extract indicating selective extraction 
by the detergent (Figure 4 line 1 and 2). The non 
reduced oxamic-acid absorbed H5N1-protein consisted 
of one conspicuous bands at ~ 85 kDa and the other less 
prominent bands at ~28 kDa, ~55 kDa and >98 kDa 
(Figure 4a, line 3). When this oxamic-acid absorbed 
H5N1-protein was purified further using gel filtration 
chromatography, the ~ 85 kDa band became more 
dominant, whereas other bands were unapparent (Figure 
4A, line 4). Under reducing condition, the ~ 85 kDa and 
>98 kDa bands were absent. Two most conspicuous 
bands, ~ 60 and ~ 28 kDa, were seen (Figure 4C, line 
4). On immunoblot analysis, the non-reduced ~ 85 KDa 
and the > 98 kDa band were recognised strongly by the 
H5N1 antiserum (Figure 4B). The ~ 60 kDa reduced 
band was also strongly recognised but not the ~28 kDa. 
 
 
 
 
Figure 1. Chromatogram of oxamic-acid absorbed H5N1 protein on Superdex-200 column. The dominant peak contained 
enzymatically active NA.  
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Figure 2. Recognition in ELISA of the oxamic-acid purified NA at different concentration by antibodies against amino-acid-sequence 
in the middle of H5N1 neuraminidase ((N1-Neuraminidase (IN)), carboxyl-terminal H5N1 neuraminidase (N1-
Neuraminidase (CT)), amino-acid-sequence in the middle of H5N1-hemagglutinin ((H5-Hemagglutinin (IN)), and amino-
terminal H5N1 hemagglutinin (N1-Hemagglutinin (NT)) 
 
 
 
 
 
Figure 3. Recognition in ELISA of the gel-filtration-purified NA at different concentration by antibodies against amino-acid-sequence 
in the middle of H5N1 neuraminidase ((N1-Neuraminidase (IN)), carboxyl-terminal H5N1 neuraminidase (N1-
Neuraminidase (CT)), amino-acid-sequence in the middle of H5N1-hemagglutinin ((H5-Hemagglutinin (IN)), and amino-
terminal H5N1 hemagglutinin (N1-Hemagglutinin (NT)) 
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Figure 4.  SDS-PAGE and immunoblot analysis on samples taken from different stages of H5N1-neuraminidase purification.  
Samples in A and B were devoid of reducing agent (non reduced), whereas samples in C and D reduced by β-
mercaptoethanol  
 
Collumn 1= H5N1 virus  
Collumn 2= Triton-100-extracted H5N1 virus  
Collumn 3= aminophenyl-oxamic-absorbed H5N1- protein  
Collumn 4= gel-filtration-purified-aminophenyl-oxamic absorbed protein  
A and C= SDS-PAGE gels stained with Coomasie blue  
B and D= blots probed with serum from chicken immunised with commercial H5N1 vaccine 
 
DISCUSSION 
This study shows that H5N1 neuraminidase is 
effectively purified using oxamic-acid-agarose affinity 
column chromatography, followed by gel-filtration 
chromatography. The purified NA was enzymatically 
active and recognised by specific antibodies raised 
against H5N1 neuraminidase. Triton X-100, used in this 
study, extracted mainly the surface glycoproteins, HA 
and the NA, from the core viral proteins (HOCART et 
al., 1995; JOHANSSON et al., 1988). Since the 
concentration of HA is much higher than that of NA, 
the most likely contaminating proteins in the NA 
purification would be the HA (JOHANSSON et al., 1989). 
In our purified NA, however, the presence of HA could 
not be detected either by hemagglutination assay (HA) 
or ELISA using specific antibodies against the 
glycoprotein. This is desirable especially if the purified 
NA is to be used for the development of a diagnostic 
test, especially the heterologous NA DIVA test which 
requires a complete removal of HA. 
Being insoluble in water, the NA required 
detergents in its extraction and purification. Glycoside 
detergents have been used for extraction and 
purification of influenza-virus NA (JOHANSSON et al., 
1989; POWERS et al., 1996). These detergents have 
some important advantages because they are mild, can 
be removed by dialysis and and do not absorb 280 nm 
light, at which wave length proteins are usually 
detected. However, this detergent is prohibitively 
expensive. Polyoxyethylene detergents such as Triton 
x-100 and Triton x-114 are also effective for extraction 
of surface glycoproteins of influenza virus (BRETT and 
JOHANSSON, 2005; GERENTES et al., 1998; GERENTES et 
al., 1996).  Tritons are cheap and widely available but 
they can not be removed by dialysis and absorb 280 nm 
wavelenght. For extraction of surface glycoproteins in 
this study, we used Triton x-100 since this stage did not 
require the dialysis and measurement at 280 nm. In the 
later steps of purification, Octyl β-D-glucopyranoside 
was used because the steps required measurement at 
280 nm and concentration by ultrafiltration. We found 
that the combination of those detergents was 
satisfactory. 
An alternative to using detergents in the NA 
purification is to using proteases such pronase, trypsin 
or bromelain (AITKEN and HANNOUN, 1980; 
BURMEISTER et al., 1991; MCKIMM-BRESCHKIN et al., 
1991; WARD et al., 1982). These proteases are believed 
to selectively cleave the NA head from the rest of the 
virion. The NA head having high molecular weight can 
be separated from the proteases which have much lower 
molecular weight by a gel filtration chromatography. In 
addition, the NA head is relatively easier to manipulate 
because it is soluble in water. In our experience with the 
trypsin or pronase, however, the yield of purified NA 
was very low and enzymatically inactive (Data not 
presented). The reason for the low yield was unknown, 
but we speculate that the NA was digested by the 
protease into small fragments.  
The most common method for assay of enzymatic 
activity of NA are the thiobarbiturate assay (TARIGAN et 
al., 2007; WARREN, 1959) and Umbellyferyl assay 
(BUXTON et al., 2000; LAMBRE et al., 1989; POTIER et 
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al., 1979; WETHERALL et al., 2003). The later is much 
more sensitive and accurate but it requires a fluorometer 
to measure the intensity of fluorescence. Most 
laboratories are not equipped with a fluorometer and 
this restricts the use of the assay. In this study, we use a 
small fluorescence light similar to that used by 
shopkeepers to detect counterfeit money to substitute 
the fluorometer. Although this modified assay was 
unsuitable for quantitative purpose due to difficulty in 
determining the endpoint dilution, the assay was very 
simple, rapid and sensitive. More importantly, the assay 
was unaffected by the presence of detergent used in this 
study. The thiobarbiturate assay was quantitative and 
did not require specialised equipment however the 
assay did not work in the presence of detergents used in 
this study. 
The binding selectivity of oxamic-acid agarose for 
the H5N1 neuraminidase was satisfactory. 
Nevertheless, a single cycle of loading sample into the 
column and eluting the bound NA was not sufficient to 
recover all NA contained in the samples. Three or four 
cycles of sample loading were required to completely 
absorb the NA in the loading sample, and this inevitably 
resulted in voluminous eluate. The use of octyl 
glucopyranoside in the elution buffer was of advantage 
because the elute needed to be concentrated. The purity 
of NA after the oxamic-acid agarose chromatography 
was quite high and did not contain any detectable HA. 
Neuraminidase preparation with such extent of purity is 
likely to be adequate for a number of applications. 
When higher degree of purity was required a gel 
filtration chromatography as additional purification 
step, as shown in this study, was necessary. 
The NA of influenza-A virus is a mushroom-shaped 
glycoprotein composed of four identical, single-chain 
polypeptide (FIELDS et al., 1981). When the NA is 
analysed on SDS PAGE under reducing condition, the 
tetrameric glycoprotein dissociates completely into 
monomer (DEROO et al., 1996; MCKIMM-BRESCHKIN et 
al., 1991). Once detached from the virion, the NA 
easily dissociates. Previous studies have demonstrated 
that a NA derived from expression of H3N2-NA gene 
in insect cells existed in a mixture of three forms ~ 220 
kDa tetrameric, ~130 kDa dimeric and ~54 kDa 
monomeric forms, even in the absence of any reducing 
agents. When the preparation was analysed by SDS 
PAGE under non-reducing condition the tetrameric and 
dimeric forms migrated as dimeric chains of 110 kDa 
(DEROO et al., 1996). In the present study, the ~28 kDa 
band which was dominant in the reducing but not in 
non-reducing SDS PAGE is considered to be the 
fragment of monomeric NA. The reason why this 
fragment was not recognised by the H5N1 antiserum is 
unknown but the fragment might represent the non 
immunogenic part of the NA. The >98 kDa, the ~85 
kDa and the ~55 kDa bands that appeared on the non-
reducing SDS PAGE were considered to be the 
tetarmeric, dimeric and monomeric forms, respectively. 
In line with DEROO et al., (1996), the tetrameric and 
dimeric forms were dissociated into monomeric form 
under reducing condition. The ~85 kDa- dimeric NA 
obtained in this study might be the conjugation between 
a complete monomer with an incomplete, -non-
immunogenic part of monomer. Under reducing 
condition this conjunction dissociated into ~60 kDa 
complete and ~28 kDa incomplete monomers.  
The fact that the purified NA was recognised 
strongly by the antibodies against the middle but only 
weakly against the C-terminal regions of the NA protein 
of a H5N1 virus may indicates that the NA purified in 
this study has high similarity in the middle but only low 
similarity in the C terminus with the H5N1 
neuraminidase against which the antibodies were raised. 
The ~28-kDa incomplete, non immunogenic 
monomeric form is probably derived from the N or C 
terminus of the NA. 
In conclusion, our results demonstrate the 
advantages of Triton X-100 and Octyl glucopyranoside 
detergents in solubilising the NA from the virion. High 
purity of NA was obtained by the use of an oxamic-
acid-agarose-affinity chromatography, and gel filtration 
chromatography on Superdex-200 column further 
improved the purity. The Umbelliferyl assay offered a 
rapid and sensitive assay to monitor the enzymatic 
activity of the neuraminidase. 
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